Imperial College London
Alternate

Professor Neil Poulter

Faculty of Medicine, School of Public Health

Professor of Preventive Cardiovascular Medicine.
 
 
 
//

Contact

 

+44 (0)20 7594 3446n.poulter

 
 
//

Assistant

 

Mrs Ranjit Rayat +44 (0)20 7594 3445

 
//

Location

 

55Stadium HouseWhite City Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Mann:2017:10.1056/NEJMoa1616011,
author = {Mann, JFE and Orsted, DD and Brown-Frandsen, K and Marso, SP and Poulter, NR and Rasmussen, S and Tornoe, K and Zinman, B and Buse, JB},
doi = {10.1056/NEJMoa1616011},
journal = {NEW ENGLAND JOURNAL OF MEDICINE},
pages = {839--848},
title = {Liraglutide and Renal Outcomes in Type 2 Diabetes},
url = {http://dx.doi.org/10.1056/NEJMoa1616011},
volume = {377},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - BACKGROUNDIn a randomized, controlled trial that compared liraglutide, a glucagon-like pep-tide 1 analogue, with placebo in patients with type 2 diabetes and high cardio-vascular risk who were receiving usual care, we found that liraglutide resulted inlower risks of the primary end point (nonfatal myocardial infarction, nonfatalstroke, or death from cardiovascular causes) and death. However, the long-termeffects of liraglutide on renal outcomes in patients with type 2 diabetes are un-known.METHODSWe report the prespecified secondary renal outcomes of that randomized, con-trolled trial in which patients were assigned to receive liraglutide or placebo. Thesecondary renal outcome was a composite of new-onset persistent macroalbumin-uria, persistent doubling of the serum creatinine level, end-stage renal disease, ordeath due to renal disease. The risk of renal outcomes was determined with theuse of time-to-event analyses with an intention-to-treat approach. Changes in theestimated glomerular filtration rate and albuminuria were also analyzed.RESULTSA total of 9340 patients underwent randomization, and the median follow-up ofthe patients was 3.84 years. The renal outcome occurred in fewer participants inthe liraglutide group than in the placebo group (268 of 4668 patients vs. 337 of4672; hazard ratio, 0.78; 95% confidence interval [CI], 0.67 to 0.92; P=0.003). Thisresult was driven primarily by the new onset of persistent macroalbuminuria,which occurred in fewer participants in the liraglutide group than in the placebogroup (161 vs. 215 patients; hazard ratio, 0.74; 95% CI, 0.60 to 0.91; P=0.004). Therates of renal adverse events were similar in the liraglutide group and the placebogroup (15.1 events and 16.5 events per 1000 patient-years), including the rate ofacute kidney injury (7.1 and 6.2 events per 1000 patient-years, respectively).CONCLUSIONSThis prespecified secondary analysis shows that, when added to usual care, lira-glutide resulted in lower rates of the devel
AU  - Mann,JFE
AU  - Orsted,DD
AU  - Brown-Frandsen,K
AU  - Marso,SP
AU  - Poulter,NR
AU  - Rasmussen,S
AU  - Tornoe,K
AU  - Zinman,B
AU  - Buse,JB
DO  - 10.1056/NEJMoa1616011
EP  - 848
PY  - 2017///
SN  - 0028-4793
SP  - 839
TI  - Liraglutide and Renal Outcomes in Type 2 Diabetes
T2  - NEW ENGLAND JOURNAL OF MEDICINE
UR  - http://dx.doi.org/10.1056/NEJMoa1616011
UR  - http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000408626400007&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
UR  - http://hdl.handle.net/10044/1/54155
VL  - 377
ER  -
Download